Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TM4SF20-ADC
- Development stage
- Preclinical
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TM4SF20-ADC is an antibody-drug conjugate (ADC) designed to target transmembrane 4 L six family member 20 (TM4SF20), a tetraspanin-like protein that facilitates liver metastasis in pancreatic ductal adenocarcinoma (PDAC) by scaffolding the DDR1-IRS4 signaling complex. The conjugate consists of a TM4SF20-specific monoclonal antibody linked to deruxtecan (DXD), a potent topoisomerase I inhibitor. By binding to TM4SF20 on the surface of cancer cells, the ADC is internalized and releases its cytotoxic payload, leading to DNA damage and apoptosis. Preclinical studies presented at AACR 2026 demonstrate that TM4SF20-ADC effectively eliminates both primary PDAC tumors and established liver metastases in orthotopic mouse models, suggesting it as a potential therapeutic strategy for advanced pancreatic cancer.
- Other names
- TM4SF20-directed antibody-drug conjugateTM-4SF20-directed antibody-drug conjugateTM 4SF20-directed antibody-drug conjugateαTM4SF20-DXD
02
Targets
TM4SF1 (Transmembrane 4 L6 family member 1)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on TM4SF20-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TM4SF20-ADC.